Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus
Hydroxychloroquine versus tacrolimus for the treatment of persistently active systemic lupus erythematosus
复制标题
羟氯喹与他克莫司治疗持续活动性系统性红斑狼疮的比较
DOI：
10.1093/mr/roab010
复制
发表时间：
2021
影响因子：
2.2
通讯作者：
Niiro Hiroaki
中科院分区：
文献类型：
--
作者：
Ayano Masahiro;Kimoto Yasutaka;Mitoma Hiroki;Akahoshi Mitsuteru;Ono Nobuyuki;Arinobu Yojiro;Akashi Koichi;Horiuchi Takahiko;Niiro Hiroaki
ObjectivesWe aim to reveal the efficacy of hydroxychloroquine（HCQ）compared with tacrolimus（TAC），a immunosuppressant，in patients with systemic lupus erythematosus（SLE）with persistent activity on standard treatment.MethodsWe retrospectively compared the efficacy and safety of the treatment between 18 patients receiving HCQ and 27 patients receiving TAC.在本研究开始时，没有患者处于狼疮低疾病活动状态（LLDAS）。疗效终点是在没有额外免疫抑制剂的情况下达到LLDAS的累积发生率、药物继续使用率和无治疗失败生存率。安全性终点是不良事件的频率。结果HCQ组8例（44.4%）患者和TAC组10例（37.0%）患者在随访期间实现LLDAS;因此，两种治疗的LLDAS实现的累积发生率几乎相同。两组之间的药物持续使用率和无治疗失败生存率也没有差异。不良事件的频率显示两组之间没有明显的差异。ConclusionsThe疗效和安全性的附加治疗与HCQ是类似的那些与TAC。持续活动性SLE患者可以从HCQ中获益，至少可以达到低疾病活动性。
ObjectivesWe aimed to reveal the effectiveness of hydroxychloroquine (HCQ) compared with tacrolimus (TAC), an immunosuppressive agent, in patients with systemic lupus erythematosus (SLE) with persistent activity on standard treatment.MethodsWe retrospectively compared the efficacy and safety of the treatment between 18 patients receiving HCQ and 27 patients receiving TAC. None of the patients were in the lupus low disease activity state (LLDAS) at the beginning of this study. The efficacy end points were the cumulative incidence of LLDAS attainment without additional immunosuppressive agents, drug continuation rate, and treatment failure–free survival. The safety end point was the frequency of adverse events.ResultsEight (44.4%) patients in the HCQ group and 10 (37.0%) patients in the TAC group achieved LLDAS during the follow-up period; thus, the cumulative incidences of LLDAS attainment of the two treatments were nearly identical. The drug continuation and treatment failure–free survival rates were also not different between the two groups. The frequency of adverse events showed no clear differences between the two groups.ConclusionsThe efficacy and safety of an add-on treatment with HCQ are similar to those with TAC. Patients with persistently active SLE can benefit from HCQ in efforts to achieve at least low disease activity.